Cryptococcal meningitis: 12 mg/kg on first day, followed by 6 mg/kg/day (or 12 mg/kg/day based on medical judgment of patient’s response). Recommended duration is 10 to 12 wk after CSF becomes culture negative.
Newborns: Experience is limited to pharmacokinetic studies in premature newborns. Prolonged half-life has been noted. These children, in the first 2 wk of life, should receive the same mg/kg dosage as other children, but administered every 72 h. After the first 2 wk, dose every day.
Adults:PO / IV 400 mg first day, followed by 200 mg every day thereafter (400 mg may be used) for 10 to 12 wk after CSF culture is negative for initial meningitis; 200 mg ever day for suppression of relapse of cryptococcal meningitis.
Oropharyngeal or Esophageal Candidiasis
Adults:PO / IV 200 mg first day, followed by 100 mg every day thereafter for minimum of 2 wk for oropharyngeal candidiasis, or for 3 wk and at least 2 wk following resolution of symptoms for esophageal candidiasis.
Children:PO / IV 6 mg/kg on first day, followed by 3 mg/kg every day thereafter for minimum of 2 wk for oropharyngeal candidiasis or 3 wk (at least 2 wk after symptom resolution) for esophageal candidiasis.
Prevention of Candidiasis in Bone Marrow Transplant
Adults:PO / IV 400 mg every day; in patients with anticipated severe granulocytopenia (less than 500 neutrophils/mm3 ), start fluconazole several days before anticipated onset and continue 7 days after neutrophil count rises more than 1,000 cells/mm3 .
Systemic Candida Infections
Adults: Optimal therapeutic dosage and duration not established; however, in noncomparative studies of small numbers of patients, doses up to 400 mg/day have been used.
UTIs and Peritonitis
Adults: Daily doses of 50 to 200 mg have been used in open, noncomparative studies of small numbers of patients.